ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 12 of 130 for:    PAP children

Continuous Positive Airway Pressure (CPAP) After Adenotonsillectomy in Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01554527
Recruitment Status : Completed
First Posted : March 15, 2012
Results First Posted : January 14, 2019
Last Update Posted : January 14, 2019
Sponsor:
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI)
Michigan Technological University
Information provided by (Responsible Party):
Ronald D. Chervin, M.D., M.S., University of Michigan

Brief Summary:
Obstructive sleep-disordered breathing (SDB) affects 2-3% of children and may lead to problems with nighttime sleep and daytime behavior, learning, sleepiness, and mood. Adenotonsillectomy (AT) is the second most common surgical procedure in children. It is now performed more often for suspected SDB than for any other indication. However, recent studies indicate that many if not most children still have SDB after AT, and many still have learning or behavioral problems associated with SDB. The goals of this study are: (1) to assess the extent that behavior, cognition, and sleepiness in children can improve with Continuous positive airway pressure (CPAP) treatment after AT, and (2) to identify which patients stand to gain most from post-operative assessment and treatment.

Condition or disease Intervention/treatment Phase
Sleep Apnea, Obstructive Sleep Apnea Syndromes Child Behavior Disorders Attention Deficit Disorder With Hyperactivity Disorders of Excessive Somnolence Procedure: CPAP treatment Other: No CPAP treatment Not Applicable

Detailed Description:

Obstructive sleep-disordered breathing (SDB) affects at least 2-3% of children and may have substantial adverse impact on behavior and cognition. Adenotonsillectomy (AT), the second most common surgical procedure in children, is now performed more often for suspected SDB than for any other indication. However, recent studies among an increasingly obese population now show something alarming: many if not most children still have SDB after AT, and many still suffer from residual neurobehavioral morbidity. Furthermore, the investigators' ongoing, 12-year, NIH-funded research has shown that standard preoperative polysomnographic measures of SDB do not consistently predict post-AT improvement in behavior and cognition. This may arise in part because many children after AT still have SDB, and because linear relationships between standard SDB measures and neurobehavioral morbidity may not exist. Even at subtle levels, SDB may promote significant neurobehavioral morbidity. Some have suggested that polysomnography may be more important after AT than before AT. However, in practice few children receive polysomnography before AT, and even fewer after AT, when continuous positive airway pressure (CPAP) could still provide definitive relief from SDB. Preliminary data from our group suggest that CPAP after AT is well-tolerated by most children and may provide significant benefit. However, virtually no published evidence exists to address critical clinical questions: which children benefit most from CPAP after AT; what role can clinical symptoms or polysomnography play in that determination; and what neurobehavioral gains are achieved by CPAP after AT?

The investigators therefore will undertake a highly practical, clinical study with two main goals: (1) to assess the extent that behavior, cognition, and sleepiness in children can improve with CPAP after AT, and (2) to identify which patients stand to gain most from post-operative assessment and treatment. This research will use reversible SDB-related neurobehavioral morbidity as the criteria by which to judge the utility of clinical symptoms and polysomnography in identification of candidates for CPAP after AT.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Sleep-Disordered Breathing and CPAP After Adenotonsillectomy in Children
Study Start Date : March 2012
Actual Primary Completion Date : October 29, 2017
Actual Study Completion Date : October 29, 2017

Arm Intervention/treatment
Experimental: CPAP treatment
Children randomized to this arm will receive 6 months of CPAP (or BPAP) treatment, beginning at approximately 4 months after AT, in addition to standard of care. For analysis purposes those children who were non-adherent (CPAP use <4 hours per night) vs. adherent (CPAP use at least 4 hours per night) will be analyzed separately.
Procedure: CPAP treatment
6 months of treatment with PAP (CPAP or BPAP)
Other Names:
  • Continuous positive airway pressure device (CPAP)
  • Bi-level positive airway pressure device (BPAP)
  • Positive Airway Pressure device (PAP)

No CPAP treatment
Children randomized to this comparison arm will not be treated with CPAP or BPAP, but will be followed for approximately 10 months after AT while receiving standard of care.
Other: No CPAP treatment
Children randomized to the comparison group will receive routine care
Other Names:
  • Comparison group
  • Control group




Primary Outcome Measures :
  1. Change in Behavioral Index After 6 Months of CPAP or No-CPAP [ Time Frame: assessed as change from baseline to 6 months of CPAP therapy or no-CPAP ]
    The sum of the T-scores of The Conners' Parent Rating Scales (CPRS-R:L, ADHD index) and the Child Behavior Checklist (CBCL, Attention Deficit/Hyperactivity Problems) are used to construct the primary study outcome measure Behavioral Index. Behavioral index is a T score (adjusted for age and gender) with a range of "<10" to ">90" - where higher scores mean worse behavior and lower scores mean better behavior, so a negative change score represents an improvement in behavior. T-scores with a mean of 50 and SD of 10 are computed.


Secondary Outcome Measures :
  1. Change in Cognition as Shown by NIH Toolbox Composite Score [ Time Frame: assessed as change from baseline to 6 months of CPAP therapy or no-CPAP ]
    Scores are reported as standardized scores with a mean of 100 and SD of 15. Minimum value 40 and Maximum value 160. Higher scores are better

  2. Change in Sleepiness as Measured by Epworth Sleepiness Scale [ Time Frame: assessed as change from baseline to 6 months of CPAP therapy or no-CPAP ]
    Epworth Sleepiness Scale scores range from 0 to 24 where higher scores mean greater sleepiness.

  3. Change in Sleepiness After AT as Measured by Multiple Sleep Latency Test (MSLT) [ Time Frame: assessed as change from baseline to 6 months of CPAP therapy or no-CPAP ]
    Multiple Sleep Latency Test (MSLT) is an objective measure of sleepiness determined by measure of brain waves and other physiological signals over a 30 minute period. This is measured for five 30 minute periods across the day and average latency to sleep for each participant across those times were used to calculate the mean sleep latency. The score is measured in how quickly one would fall asleep, measured in minutes, so a negative number of minutes in the change score means that participants fell asleep more quickly than previously.

  4. Change in Quality of Life as Measured by Peds QL [ Time Frame: assessed as change from baseline to 6 months of CPAP therapy or no-CPAP ]
    Peds-QL is a quality of life symptom measurement with a score range of 0 to 100. Higher scores are better quality of life

  5. CPAP Adherence as Measured by Number of Participants Who Used the CPAP Consistently. [ Time Frame: Starting at 4 months after AT and continuing through 10 months after AT ]
    CPAP adherence data will be downloaded from CPAP machines. It is defined for this study as using the CPAP machine for at least an average of 4 hours per night during the last 60 days of the assignment.


Other Outcome Measures:
  1. Change in Cognition as Measured by Fluid Cognition Scores [ Time Frame: assessed as change from baseline to 6 months of CPAP therapy or no-CPAP ]
    Scores are reported as standardized scores with a mean of 100 and SD of 15. Minimum value 40, Maximum value 160. Higher scores are better

  2. Change in Cognition After AT as Shown by Academic Achievement [ Time Frame: assessed as change from baseline to 6 months of CPAP therapy or no-CPAP ]
    Academic achievement mean score is a standardized score with a mean of 100 and SD 15. Minimum value 40 and Maximum value 160. Higher scores are better



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   5 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Children ages 5-12 years old,
  2. Scheduled for an adenotonsillectomy for treatment of sleep apnea,
  3. Child must provide assent, and
  4. Parent or legal guardian must be able to speak and read English, and agree to the study.

Exclusion Criteria:

  1. No siblings of children already enrolled in the study,
  2. Children who expect to have another surgery (in addition to AT) during the period of participation in this study,
  3. Neurological, psychiatric, or medical conditions, or social factors that may affect test results, prevent children from returning for required study visits, or interfere with the study treatment, or
  4. Certain medications that affect sleepiness or alertness, for example:

    • Stimulants (such as Ritalin, Adderall, or Concerta),
    • Sleep aides (such as Melatonin, Ambien, or Ativan), or
    • Sedating medicines (such as Benadryl, Klonopin, Xanax, or Valerian).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01554527


Locations
United States, Michigan
University of Michigan Health System
Ann Arbor, Michigan, United States, 48109
Sponsors and Collaborators
University of Michigan
National Heart, Lung, and Blood Institute (NHLBI)
Michigan Technological University
Investigators
Principal Investigator: Ronald D. Chervin, MD, MS University of Michigan
  Study Documents (Full-Text)

Documents provided by Ronald D. Chervin, M.D., M.S., University of Michigan:

Responsible Party: Ronald D. Chervin, M.D., M.S., Professor of Neurology, University of Michigan
ClinicalTrials.gov Identifier: NCT01554527     History of Changes
Other Study ID Numbers: F029661-00
1R01HL105999-01A1 ( U.S. NIH Grant/Contract )
First Posted: March 15, 2012    Key Record Dates
Results First Posted: January 14, 2019
Last Update Posted: January 14, 2019
Last Verified: January 2019

Keywords provided by Ronald D. Chervin, M.D., M.S., University of Michigan:
polysomnography
child
continuous positive airway pressure
tonsillectomy
neuropsychological tests
cognition
sleepiness
behavior

Additional relevant MeSH terms:
Child Behavior Disorders
Disease
Apnea
Sleep Apnea Syndromes
Attention Deficit Disorder with Hyperactivity
Sleep Apnea, Obstructive
Mental Disorders
Disorders of Excessive Somnolence
Pathologic Processes
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Sleep Disorders, Intrinsic
Dyssomnias
Sleep Wake Disorders
Nervous System Diseases
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders